Volume 4.48 | Dec 6

Mammary Cell News 4.48 December 6, 2012
Mammary Cell News
     In this issue: Publications | Reviews Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Retinoblastoma and Phosphate and Tensin Homolog Tumor Suppressors: Impact on Ductal Carcinoma In Situ Progression
The association of two major tumor suppressor genes, retinoblastoma and phosphatase and tensin homolog, with risk of any ipsilateral breast event or progression to invasive breast cancer was analyzed using data from 236 ductal carcinoma in situ patients treated with breast conserving surgery with long-term follow-up. [J Natl Cancer Inst] Abstract | Press Release

[Watch the One-Minute Video] Detect Cancer Stem Cells with ALDEFLUOR™.
PUBLICATIONS (Ranked by impact factor of the journal)


KIF14 Negatively Regulates Rap1a-Radil Signaling during Breast Cancer Progression
Researchers report that kinesin KIF14 associates with the PDZ domain of Radil and negatively regulates Rap1-mediated inside-out integrin activation by tethering Radil on microtubules. The depletion of KIF14 led to increased cell spreading, altered focal adhesion dynamics, and inhibition of cell migration and invasion. [J Cell Biol] Abstract

Targeting Galectin-1 Overcomes Breast Cancer Associated Immunosuppression and Prevents Metastatic Disease
Scientists investigated the contribution of tumor galectin-1 to tumor growth, metastasis and immunosuppression in breast cancer. [Cancer Res] Abstract

Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors
The authors examined the effects of phosphatidylinositol-3 kinase (PI3K) blockade in trastuzumab-resistant breast cancer cell lines. Treatment with the pan-PI3K inhibitor XL147 and trastuzumab reduced proliferation and pAKT levels, triggering apoptosis of trastuzumab-resistant cells. [Cancer Res] Abstract

Elevated Lipogenesis in Epithelial Stem-Like Cell Confers Survival Advantage in Ductal Carcinoma In Situ of Breast Cancer
Researchers examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma in situ (DCIS) of breast cancer and found that these genes were significantly upregulated in DCIS. [Oncogene] Abstract

Targeting Carbonic Anhydrase IX Depletes Breast Cancer Stem Cells within the Hypoxic Niche
The authors demonstrated that inhibition of carbonic anhydrase IX (CAIX) expression or activity with novel small-molecule inhibitors in breast cancer cell lines, or in primary metastatic breast cancer cells, results in the inhibition of breast cancer stem cell expansion in hypoxia. They identified the mTORC1 axis as a critical pathway downstream of CAIX in the regulation of cancer stem cell function. [Oncogene] Abstract

Differential Gene Expression in Nuclear Label-Retaining Cells in the Developing Mouse Mammary Gland
Scientists labeled newly forming mammary stem cells with the thymidine analog 5-ethynl-2’-deoxyuridine for two weeks during allometric ductal expansion. Cells that incorporate and retain the nuclear label following extended chase periods are termed label-retaining cells. [Stem Cell Dev] Abstract

Activation of the Unfolded Protein Response Bypasses Trastuzumab-Mediated Inhibition of the PI-3K Pathway
Researchers tested the hypothesis that induction of the unfolded protein response could override HER2 inhibition by trastuzumab, leading to the re-activation of growth signaling and the activation of the downstream target Lipocalin 2. [Cancer Lett] Abstract

Immunohistochemical Characterization and Functional Identification of Mammary Gland Telocytes in the Self-Assembly of Reconstituted Breast Cancer Tissue In Vitro
Investigators co-cultured primary isolated telocytes and other breast stromal cells with breast cancer EMT-6 cells in collagen/Matrigel scaffolds to reconstitute breast cancer tissue in vitro. [J Cell Mol Med] Full Article

Delineation of Breast Cancer Cell Hierarchy Identifies the Subset Responsible for Dormancy
The authors report on a hierarchy of breast cancer cells with the most immature subset (Oct4hi/CD44hi/med/CD24−/+) demonstrating chemoresistance, dormancy, and stem cell properties: self-renewal, serial passaging ability, cycling quiescence, long doubling time, asymmetric division, high metastatic and invasive capability. [Sci Rep] Full Article


High Stearoyl-CoA Desaturase 1 Expression Is Associated with Shorter Survival in Breast Cancer Patients
The authors aimed to determine the relationship between stearoyl-CoA desaturase 1 expression level and clinical-pathologic characteristics and survival of patients with breast cancer. Fine-needle aspirates were collected from the primary tumors of 250 patients with stage I-III breast cancer. [Breast Cancer Res Treat] Abstract

A Novel Finding of Sentinel Lymphatic Channels in Early Stage Breast Cancer Patients: Which May Influence Detection Rate and False-Negative Rate of Sentinel Lymph Node Biopsy
Researchers aimed to investigate the sentinel lymphatic channels (SLCs) in the cancerous breast. Whether the type of SLCs influenced the detection rate and false-negative rate of sentinel lymph node biopsy was also assessed. [PLoS One] Full Article

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.

Ductal Carcinoma In Situ, Sentinel Lymph Nodes and Low Volume Metastatic Disease and Reporting of Neoadjuvant Chemotherapy Specimens
The authors examined new insights into the classification and molecular biology of ductal carcinoma in situ, the pathological handling of sentinel lymph node biopsies and the identification of low volume disease and the handling and reporting of specimens after neoadjuvant therapy. [Clin Oncol] Abstract

Mayo Clinic: Less Invasive Surgery Detects Residual Breast Cancer in Lymph Nodes after Chemotherapy
A study conducted through the American College of Surgeons Oncology Group and led by Judy Boughey, M.D. a breast surgeon at Mayo Clinic shows that a less invasive procedure known as sentinel lymph node surgery successfully identified whether cancer remained in lymph nodes in 91 percent of patients with node-positive breast cancer who received chemotherapy before their surgery. [Press release from Mayo Clinic discussing research presented at the 2012 Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio] Press Release

Extending Duration of Adjuvant Tamoxifen Treatment to Ten Years Reduced Risk for Late Breast Cancer Recurrence, Improved Survival
Ten years of adjuvant treatment with tamoxifen provided women with estrogen receptor-positive breast cancer greater protection against late recurrence and death from breast cancer compared with the current standard of five years of tamoxifen, according to the international ATLAS (Adjuvant Tamoxifen – Longer Against Shorter) study. [Press release discussing research presented at the 2012 Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio] Press Release

Higher Doses of Fulvestrant Prolonged Survival in Patients with Advanced Breast Cancer
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptorpositive breast cancer. [Press release discussing research presented at the 2012 Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, San Antonio] Press Release


Two Leading Researchers to Be Honored at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium
The 2012 Cancer Therapy & Research Center-American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium will honor two leading breast cancer researchers during its 35th annual symposium. Kornelia Polyak, M.D., Ph.D., will receive the 2012 AACR Outstanding Investigator Award for Breast Cancer Research, and Mina J. Bissell, Ph.D., will present the 2012 AACR Distinguished Lectureship in Breast Cancer Research. [American Association of Cancer Research] Press Release

The Breast Cancer Research Foundation® Announces First Grant from Newly Established Evelyn H. Lauder Founder’s Fund to Exceed $8 Million
The Breast Cancer Research Foundation announced plans for the first grant made from the newly established Evelyn H. Lauder Founder’s Fund. More than $8 million will support a large multi-institutional, international research project, to be carried out over two to three years, that will have implications for the management of not only breast cancer, but other types of cancer as well. [The Breast Cancer Research Foundation]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW American Association for Cancer Research Annual Meeting 2013
April 6-10, 2013
Washington, United States

our events page to see a complete list of events in the mammary cell community.


Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Assistant Professor – Breast Cancer (Cedars-Sinai Medical Center)

Principal Investigator – Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position – Genetic Biomarkers in Breast Cancer (Rush University Medical Center)

Postdoctoral Position – Functional Characterization of Novel Candidate Oncogenes Implicated in Breast Cancer (The Netherlands Cancer Institute)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us